interferon alpha 21Genealiases: IFN-alphaI · LeIF F · leIF-F
Q-omics provides the consensus-scored IFNA21 profile across patient tissues and cancer cell-line models. IFNA21 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, IFNA21 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, IFNA21 RNA expression shows 10,313 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, LUSC, and THYM as cancer lineages where IFNA21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFNA21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFNA21 survival associations across molecular data types. IFNA21 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFNA21 RNA expression–survival associations across cancer types. High IFNA21 expression shows unfavorable associations in KIRP, ACC and THCA, but favorable associations in SKCM, HNSC and PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for IFNA21 RNA expression.
This table summarizes IFNA21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for IFNA21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFNA21 shows lower tumor expression in LUSC, READ, THCA, COAD and KICH and higher tumor expression in BRCA. The LUSC box plot shows higher IFNA21 RNA expression in normal versus tumor tissue (log2 FC = −0.054, t-test p < 0.001).
This table shows molecular features associated with IFNA21 in patient tissues and cancer cell lines. In patient samples, IFNA21 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFNA21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Myeloma.
